Chinese biopharma known for diagnostic reagents and vaccines, including its homegrown HPV vaccine and infectious-disease test kits.
Chinese biopharma known for diagnostic reagents and vaccines, including its homegrown HPV vaccine and infectious-disease test kits.
Earns from two different businesses: vaccines, sold in China largely to provincial disease-control centres that supply community clinics where people pay out of pocket, and diagnostic kits sold to hospitals and labs through distributors. Its Innovax subsidiary makes the HPV vaccine, which the WHO pre-qualified in 2021, a step toward supply to international buyers.
In one line: A Chinese hybrid of a diagnostics maker and an HPV vaccine developer.
Moat: narrow (IP / patents, regulatory licence, brand). First Chinese maker of a homegrown 9-valent HPV vaccine, plus an established diagnostics franchise.
Headquarters: Beijing, China · Employees: 4,116
Size Beijing Wantai Biological Pharmacy Enterprise (603392.SS) is a China Health Care company (Biotechnology) with a market value of $4.20B, the 575th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥22.55 on 18 Nov 2026.
Performance Over six months the shares fell 43.0%, against +2.0% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 8.3% over the last twelve months (peer median -11.7%); the operating margin is -35.0% (peer median -38.2%).
Valuation It trades at 12.7× enterprise value to sales against a peer median of 10.3× (7th most expensive of 15).
Capital Return on invested capital runs 11.2 points below its cost of capital (7.9% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.94B | CN¥1.81B | CN¥2.24B | CN¥5.49B | CN¥11.1B |
| Revenue growth | — | -19% | -59% | -51% | — |
| Gross profit | CN¥1.27B | CN¥690M | CN¥1.24B | CN¥4.43B | CN¥9.86B |
| EBITDA | n/a | -CN¥375M | -CN¥9.47M | CN¥1.62B | CN¥5.42B |
| Net income | -CN¥456M | -CN¥398M | CN¥106M | CN¥1.25B | CN¥4.74B |
| Free cash flow | -CN¥457M | -CN¥601M | -CN¥389M | CN¥444M | CN¥3.21B |
| Capital expenditure | CN¥599M | CN¥805M | CN¥887M | CN¥1.16B | CN¥930M |
| Total debt | CN¥364M | CN¥374M | CN¥407M | CN¥399M | CN¥313M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | $4.20B | -43% | +8% | -35% | 12.7× | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| Shenzhen Kangtai Biological Products 300601.SZ | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% |
| Innovita Biological Technology 688253.SS | $915M | -28% | -28% | 11% | 14.0× | 39.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603392.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.9% | -5.3% | 6th lowest of 21 |
| 6-month return | -43.0% | +2.0% | lowest of 21 |
| Distance from 52-week high | -59.8% | -33.1% | 3rd lowest of 21 |
| Revenue growth (TTM) | +8.3% | -11.7% | 8th highest of 16 |
| Operating margin | -35.0% | -38.2% | 8th highest of 15 |
| EV / Sales | 12.7× | 10.3× | 7th most expensive of 15 |
| ROIC minus cost of capital | -11.2 pp | -18.2 pp | 6th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | 10% | 4.8× | 25.4% | +15.6% |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |